In a previously published study of a cohort of 11 pediatric B-ALL patients with the KMT2A-USP2 fusion, three patients presented with central nervous system disease and 8 patients had positive-minimal residual disease at day 33, suggesting a poor prognosis of patients carrying this fusion (39). This evidence concerns the gene USP2 and precursor B-cell acute lymphoblastic leukemia.